# Summary
EVE Health Advances Reformulated Drugs Targeting Sexual Health and Cardiovascular Markets
EVE Health Group ASX:EVE has completed research and development work on a series of reformulated drug candidates targeting sexual health and cardiovascular therapies across global pharmaceutical markets.Each program utilises the company’s proprietary drug delivery and solubilisation technologies to…
EVE Health Group has completed R&D on reformulated drug candidates targeting sexual health and cardiovascular therapies for global pharmaceutical markets. The programs leverage the company's proprietary drug delivery and solubilisation technologies to improve therapeutic outcomes. This advancement positions EVE Health to expand its presence in these high-demand therapeutic sectors.
Original Article
Read full article on TradingViewExplore More
Related News
Health rules under review
The Star | Malaysia News: National, Regional and World News · 2026.04.05
Opinion: Health care delayed, health care denied
Winnipeg Free Press – Breaking News, Sports, Manitoba, Canada · 2026.04.04
OpenLoop Health has acquired nutrition startup Season Health
2026.04.04
St. Vincent Behavioral Health Campus Expands Housing & Health Care for LA with $6M Health Net Investment
PR Newswire: press release distribution, targeting, monitoring and marketing · 2026.04.04
Health Net Invests $6 Million to Support Behavioral Health Services
2026.04.04
Health Benefits Of Walking
NDTV Doctor · 2026.04.04